Trending...
- Safe Health Zones: A Global Breakthrough to Protect Night-Shift Workers from Preventable Harm
- Wohler announces three SRT monitoring enhancements for its iVAM2-MPEG monitor and the addition of front panel PID selection of A/V/subtitle streams
- Curated Domain Name Marketplace
STUART, Fla., April 19, 2024 ~ Stuart Therapeutics, Inc., a clinical-stage ophthalmic biopharmaceutical company, is making strides in the development of therapies for various eye disorders. The company's President and CEO, Eric Schlumpf, will be presenting their latest research results at two upcoming meetings in early May.
On Friday, May 3rd, Schlumpf will be speaking at the Dry Horizons Symposium, co-sponsored by Ora, Inc. His presentation will focus on Stuart Therapeutics' innovative dry eye disease program, which is currently in a Phase 3 trial. The following day, Saturday May 4th, he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and exudative retinal indications at the Ophthalmology Innovation Source (OIS) Retina Meeting.
Both of these meetings will take place at the Four Seasons Hotel in Seattle, Washington. This provides an opportunity for Stuart Therapeutics to showcase their groundbreaking research to a wide audience of industry professionals.
More on Washingtoner
In addition to Schlumpf's presentations, members of Stuart Therapeutics' R&D team have also co-authored a poster presentation that will be presented by researchers from the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 5-9, 2024. The poster presentation titled "Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation" focuses on work done at the University of Rochester using Stuart Therapeutics' proprietary collagen mimetic peptide platform. This research aims to understand its effectiveness in reversing scleral collagen disruption in the eye, which is believed to contribute to myopia.
The study authors include Aldo Tecse, Kaitlin Wozniak, James German, Alex McMullen, Mark Buckley, Robert Baratta, Eric Schlumpf, Brian J. Del Buono, Michael Telias and Susana Marcos. This collaboration between Stuart Therapeutics and the University of Rochester highlights the company's commitment to advancing the field of ophthalmology and finding new treatments for eye disorders.
Stuart Therapeutics' presence at these upcoming meetings demonstrates their dedication to innovation and their potential to make a significant impact in the field of ophthalmology. With their cutting-edge research and promising results, they are poised to become a leader in developing therapies for anterior segment, refractive, and posterior segment eye disorders.
On Friday, May 3rd, Schlumpf will be speaking at the Dry Horizons Symposium, co-sponsored by Ora, Inc. His presentation will focus on Stuart Therapeutics' innovative dry eye disease program, which is currently in a Phase 3 trial. The following day, Saturday May 4th, he will be presenting the company's latest pre-clinical results in retinitis pigmentosa and exudative retinal indications at the Ophthalmology Innovation Source (OIS) Retina Meeting.
Both of these meetings will take place at the Four Seasons Hotel in Seattle, Washington. This provides an opportunity for Stuart Therapeutics to showcase their groundbreaking research to a wide audience of industry professionals.
More on Washingtoner
- Stratum Nutrition's OVOLUX™ Named 2025 "Collagen Ingredient of the Year" by Beauty Innovation Awards
- Sons of Liberty Museum Unveils "America at 250" Mobile Exhibit on Veterans Day 2025
- Revenue Expansion, Regulatory Momentum, and a Leadership Position in the $750 Million Suicidal Depression: NRx Pharmaceuticals (N A S D A Q: NRXP)
- North 5th Street – Between North Tacoma Avenue and North Division Avenue – to Close in Phases for Maintenance Starting December 1
- Bent Danholm Releases New Video Breaking Down the Rising Debate Over 50-Year Mortgages
In addition to Schlumpf's presentations, members of Stuart Therapeutics' R&D team have also co-authored a poster presentation that will be presented by researchers from the University of Rochester at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting from May 5-9, 2024. The poster presentation titled "Scleral collagen remodeling and repair assessed in intact eyes through Second Harmonic Generation" focuses on work done at the University of Rochester using Stuart Therapeutics' proprietary collagen mimetic peptide platform. This research aims to understand its effectiveness in reversing scleral collagen disruption in the eye, which is believed to contribute to myopia.
The study authors include Aldo Tecse, Kaitlin Wozniak, James German, Alex McMullen, Mark Buckley, Robert Baratta, Eric Schlumpf, Brian J. Del Buono, Michael Telias and Susana Marcos. This collaboration between Stuart Therapeutics and the University of Rochester highlights the company's commitment to advancing the field of ophthalmology and finding new treatments for eye disorders.
Stuart Therapeutics' presence at these upcoming meetings demonstrates their dedication to innovation and their potential to make a significant impact in the field of ophthalmology. With their cutting-edge research and promising results, they are poised to become a leader in developing therapies for anterior segment, refractive, and posterior segment eye disorders.
Filed Under: Business
0 Comments
Latest on Washingtoner
- Historic Announcement for the Global Car Rental Industry
- New Utah National Parks Guide Highlights Wheelchair Accessibility
- Siembra Brings 18 Latinx Artists Together in Brooklyn Exhibition
- Gramercy Tech Launches StoryStream
- Sensory Friendly Holiday Performance
- Turbo vs. Experts: Tracking OddsTrader's AI Performance at the NFL's Midpoint
- Outreaching.io Appoints Rameez Ghayas Usmani as CEO, Recognized as Best HARO Link Building Expert in the United States
- Winzele: A Trusted Isolation Transformer Manufacturer
- Luxury Mediterranean Estate in Gotha Sells for $1.52 Million, Closing $45,000 Over Asking
- ZEELOOL's Black Friday Sale Starts Early with Up to 80% Off Frames
- UV Weathering Test Chamber vs Xenon Arc Test Chamber: What's the Right Solution for Your Products
- Emeritus Addresses Hospital Bed Shortages with Smart Storage Solutions
- Fulton County & Grow Your World Amplify Atlanta Youth Through the Youth Audio Collective
- Spokane: Firework Thrown From a Vehicle Causes Severe Injuries to Another
- Spokane: Coffee With Council District 2 Council Members
- 2026 Oscars Betting Odds: One Battle After Another Favored for Best Picture
- Allen Field Co., Inc. Components Selected for Esko ArtiosCAD 3D Component Library
- Monroe Welcomes The Great Junk Hunt – This Vintage Market is Getting Ready for the Holidays!
- Thirteen Reasons Why Gyminny Kids Is San Diego's Best Gymnastics Gym
- Kennedy Funding Closes Challenging $3 Million Cash-Out Refinance Loan in Rural Washington State